Crinetics Pharmaceuticals (CRNX) Reports In-Line Q4 EPS

Crinetics Pharmaceuticals (NASDAQ: CRNX) reported Q4 EPS of ($0.88), in-line with the analyst estimate of ($0.88).

For earnings history and earnings-related data on Crinetics Pharmaceuticals (CRNX) click here.

You May Also Be Interested In

• Apple suing OpenAI over alleged misappropriation of trade secrets
• Delta Air Lines stock climbs on earnings beat and strong guidance
• Men’s Wearhouse owner Tailored Brands, bankrupt in 2020, files for IPO